Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OSPREY MEDICAL INC.
ARBN	152 854 923

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neville Mitchell
Date of last notice	19 May 2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	CHESS Depositary Interests (CDIs) held by N J Mitchell Superannuation Fund (Neville Mitchell has a beneficial interest in the above Fund)
Date of change	8 July 2021

<sup>+</sup> See chapter 19 for defined terms.

[N. 6. 101   1.1.   1.1		10.1
No. of securities held prior to change	61,250	Options (unquoted) (OSPAO) with exercise price of A\$0.38 per Share
	50,000	Options (unquoted) (OSPAO) with exercise price of A\$0.26 per Share
	215,000	Options (unquoted) (OSPAO) with exercise price of A\$0.23 per Share
	479,141	Options (unquoted) (OSPAO) with exercise price of A\$0.05 per Share
	627,417	Options (unquoted) (OSPAO) with exercise price of A\$0.05 per Share
	700,000	Options (unquoted) (OSPAO) with exercise price of A\$0.034 per Share
		options (unquoted) (OSPAO) o an equivalent of 4,265,616 CDIs)
	Fund	s held by N J Mitchell Superannuation Il has a beneficial interest in the above
Number of securities disposed/cancelled	Nil	
Class Issued	Options (unquot	ted)
No. of securities issued	833,873 Options (exercisable into an equivalent of 1,667,746 CDIs)	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	In accordance with Osprey's cost reduction initiatives introduced in early 2020 and the Option terms approved by stockholders on 19 June 2020, unlisted Options have been granted to Mr Mitchell in lieu of directors' fees of US\$16,250 for the period 1 April 2021 to 30 June 2021. The calculation for the number of Options issued was based upon the closing price of the Company's CDIs trading on ASX on 30 June 2021.	

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y Change of Director's Interest Notice

No of accomition hold often all and	(1.250	Ontinue (consusted) (OCDAO) 14
No. of securities held after change	61,250	Options (unquoted) (OSPAO) with exercise price of A\$0.38 per Share
	50,000	Options (unquoted) (OSPAO) with exercise price of A\$0.26 per Share
	215,000	Options (unquoted) (OSPAO) with exercise price of A\$0.23 per Share
	479,141	Options (unquoted) (OSPAO) with exercise price of A\$0.05 per Share
	627,417	Options (unquoted) (OSPAO) with exercise price of A\$0.05 per Share
	700,000	Options (unquoted) (OSPAO) with exercise price of A\$0.034 per Share
	833,873	Options (unquoted) (OSPAO) with exercise price of A\$0.04 per Share
	Totals:  2,966,681 Options (unquoted) (OSPAO) (exercisable into an equivalent of 5,933,362 CDIs)  3,000,003 CDIs held by N J Mitchell Superannuation Fund (Neville Mitchell has a beneficial interest in the above Fund)	
Nature of change  Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Grant of Options pursuant to stockholder approval granted at the Annual Meeting of Stockholders held on 19 June 2020.	

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3Y Change of Director's Interest Notice

No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

### Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above	N/A
traded during a <sup>+</sup> closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y Page 4 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.